Search Results for: STK11

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CALM2 calmodulin 2
  • CaMK IV-mediated phosphorylation of CREB
  • CaMK IV-mediated phosphorylation of CREB
  • Calmodulin induced events
  • Cam-PDE 1 activation
  • CaM pathway
  • Platelet degranulation
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • PKA activation
  • DARPP-32 events
  • Synthesis of IP3 and IP4 in the cytosol
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • eNOS activation
  • Transcriptional activation of mitochondrial biogenesis
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Stimuli-sensing channels
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Ca2+ pathway
  • Reduction of cytosolic Ca++ levels
  • Sodium/Calcium exchangers
  • Unblocking of NMDA receptors, glutamate binding and activation
  • CREB1 phosphorylation through the activation of Adenylate Cyclase
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • Ras activation upon Ca2+ influx through NMDA receptor
  • Smooth Muscle Contraction
  • Smooth Muscle Contraction
  • Activation of Ca-permeable Kainate Receptor
  • Uptake and function of anthrax toxins
  • VEGFR2 mediated vascular permeability
  • VEGFR2 mediated cell proliferation
  • Phase 0 - rapid depolarisation
  • Ion homeostasis
  • CLEC7A (Dectin-1) induces NFAT activation
  • CLEC7A (Dectin-1) induces NFAT activation
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • RAF activation
  • RAF/MAP kinase cascade
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Glycogen breakdown (glycogenolysis)
  • Glycogen breakdown (glycogenolysis)
  • Protein methylation
  • Extra-nuclear estrogen signaling
  • Loss of phosphorylation of MECP2 at T308
  • Regulation of MECP2 expression and activity
  • Ion transport by P-type ATPases
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Activation of RAC1 downstream of NMDARs
  • Activation of RAC1 downstream of NMDARs
  • Activation of AMPK downstream of NMDARs
  • Long-term potentiation
  • Long-term potentiation
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Chlorpromazine
  • Cinchocaine
  • Nicardipine
  • Fluphenazine
  • Isoflurane
  • Trifluoperazine
  • Loperamide
  • Perphenazine
  • Phenoxybenzamine
  • Felodipine
  • Melatonin
  • Promethazine
  • Pimozide
  • Nifedipine
  • Bepridil
  • Calcium
  • Aprindine
  • Deacetoxyvinzolidine
  • tert-butanol
  • Trimethyllysine
  • N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
  • Prenylamine
  • Flunarizine
  • (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
  • Myristic acid
  • Calcium citrate
  • Calcium citrate
  • Calcium citrate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium levulinate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
CBLC Cbl proto-oncogene C
CCDC180 coiled-coil domain containing 180
CCND2 cyclin D2
  • Cyclin D associated events in G1
  • Regulation of RUNX1 Expression and Activity
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Testicular cancer
CCNE1 cyclin E1
  • G0 and Early G1
  • SCF(Skp2)-mediated degradation of p27/p21
  • DNA Damage/Telomere Stress Induced Senescence
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • PTK6 Regulates Cell Cycle
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • RHOBTB3 ATPase cycle
  • Laryngeal cancer
  • Gastric cancer
CD44 CD44 molecule (Indian blood group)
  • Degradation of the extracellular matrix
  • Cell surface interactions at the vascular wall
  • Integrin cell surface interactions
  • Hyaluronan uptake and degradation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Bivatuzumab
  • Hyaluronic acid
  • Gastric cancer
CDC14B cell division cycle 14B
  • MAPK6/MAPK4 signaling
CDC37 cell division cycle 37, HSP90 cochaperone
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Downregulation of ERBB2 signaling
  • RHOBTB2 GTPase cycle
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
CDK4 cyclin dependent kinase 4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional regulation by RUNX2
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Purvalanol
  • Alvocidib
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Fostamatinib
  • Glioma
  • Malignant melanoma
  • Cervical cancer
CDK6 cyclin dependent kinase 6
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Regulation of RUNX1 Expression and Activity
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Alvocidib
  • (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol
  • Fisetin
  • Palbociclib
  • Ribociclib
  • Abemaciclib
CDKN2A cyclin dependent kinase inhibitor 2A
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Transcriptional Regulation by VENTX
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Apoptotic factor-mediated response
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of transcription factors
  • Regulation of TP53 Degradation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function
  • Evasion of Oncogene Induced Senescence Due to p14ARF Defects
  • Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects
  • Bladder cancer
  • Type II diabetes mellitus
  • Pancreatic cancer
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Chronic myeloid leukemia (CML)
  • Oral cancer
  • Penile cancer
  • Nasopharyngeal cancer
  • Glioma
  • Osteosarcoma
  • Squamous cell carcinoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Malignant islet cell carcinoma
  • Laryngeal cancer
  • Hepatocellular carcinoma
  • Esophageal cancer
  • Malignant melanoma
CDKN2B cyclin dependent kinase inhibitor 2B
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Malignant pleural mesothelioma
  • Osteosarcoma
  • Type II diabetes mellitus
CDKN2C cyclin dependent kinase inhibitor 2C
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
CFL2 cofilin 2
  • Nemaline myopathy
CRY2 cryptochrome circadian regulator 2
  • Circadian Clock
CTSB cathepsin B
  • Collagen degradation
  • Trafficking and processing of endosomal TLR
  • Assembly of collagen fibrils and other multimeric structures
  • MHC class II antigen presentation
  • Neutrophil degranulation
  • 2-Aminoethanimidic Acid
  • 3-Amino-4-Oxybenzyl-2-Butanone
  • 3-Methylphenylalanine
  • N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline
  • 2-Pyridinethiol
  • Diphenylacetic acid
  • N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane
  • N-{[(2S,3S)-3-(Ethoxycarbonyl)-2-oxiranyl]carbonyl}-L-threonyl-L-isoleucine
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE
  • BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
  • METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE
  • N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE
  • Tropical calcific pancreatitis
CYLC2 cylicin 2
CYP17A1 cytochrome P450 family 17 subfamily A member 1
  • Androgen biosynthesis
  • Glucocorticoid biosynthesis
  • Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
  • NADH
  • Progesterone
  • Spironolactone
  • Ketoconazole
  • Abiraterone
  • Cannabidiol
  • Medical Cannabis
  • Nabiximols
  • 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
  • Congenital adrenal hyperplasia (CAH)
D2HGDH D-2-hydroxyglutarate dehydrogenase
  • Interconversion of 2-oxoglutarate and 2-hydroxyglutarate
DACH1 dachshund family transcription factor 1

Page 2 out of 7 pages